The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - BMS Brazil; Genexine; Lilly
Consulting or Advisory Role - Bayer; ISU ABXIS
Research Funding - ABL Bio (Inst); ALX Oncology (Inst); Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); BeiGene (Inst); Daiichi Sankyo (Inst); Five Prime Therapeutics (Inst); Green Cross; LSK BioPharma (Inst); Macrogenics (Inst); Merck KGaA (Inst); MSD (Inst); Oncologie (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Pharmacyclics (Inst); Taiho Pharmaceutical (Inst); Y-BIOLOGICS (Inst); Zymeworks (Inst)
Phase 2 study of zolbetuximab plus mFOLFOX6 in claudin 18.2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ): ILUSTRO cohort 2.
 
Samuel J Klempner
Stock and Other Ownership Interests - TP Therapeutics
Honoraria - Natera
Consulting or Advisory Role - Astellas Pharma; Boston Biomedical; Bristol-Myers Squibb; Daiichi Sankyo/UCB Japan; Foundation Medicine; Lilly; Merck; Pieris Pharmaceuticals
Speakers' Bureau - Foundation Medicine
Research Funding - BeiGene (Inst); Leap Therapeutics (Inst)
Other Relationship - NCCN
 
Keun-Wook Lee
No Relationships to Disclose
 
Jean-Philippe Metges
Honoraria - BMS; Lilly; Novartis; Sanofi; SynCoreBio
Travel, Accommodations, Expenses - Amgen; Amgen; LEO Pharma; MSD Oncology; MSD Oncology; MSD Oncology
 
Daniel V.T. Catenacci
Honoraria - Amgen; Archer; Astellas Pharma; Bristol-Myers Squibb; Daiichi Sankyo/UCB Japan; Five Prime Therapeutics; Foundation Medicine; Genentech/Roche; Gritstone Bio; Guardant Health; Lilly; Merck; Natera; Pieris Pharmaceuticals; QED Therapeutics; Seagen; Taiho Pharmaceutical; Tempus; Zymeworks
Consulting or Advisory Role - Amgen; Astellas Pharma; Bristol-Myers Squibb; Daiichi Sankyo/UCB Japan; Genentech/Roche; Guardant Health; Guardant Health; Lilly; Merck; Seagen; Taiho Pharmaceutical; Zymeworks
Speakers' Bureau - Foundation Medicine; Genentech; Guardant Health; Lilly; Merck; Tempus
 
Fotios Loupakis
Consulting or Advisory Role - Amal Therapeutics; Amgen; Bayer; Sanofi
Speakers' Bureau - Amgen; Bayer; Roche; Sanofi
Research Funding - Amgen (Inst); Bayer (Inst); Merck Serono (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Amgen; Merck Serono; Roche
 
David H. Ilson
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; IQvia; Lilly/ImClone; Macrogenics; Merck; Pieris Pharmaceuticals; Roche/Genentech; Taiho Pharmaceutical
 
Manish A. Shah
Consulting or Advisory Role - Astellas Pharma; Lilly Japan
Research Funding - Bristol-Myers Squibb (Inst); Merck (Inst); Oncolys BioPharma (Inst)
 
Kohei Shitara
Honoraria - Abbvie; Novartis; Yakult Pharmaceutical
Consulting or Advisory Role - Abbvie; Amgen; Astellas Pharma; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; GlaxoSmithKline; Lilly; MSD; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - Astellas Pharma (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Lilly (Inst); Mediscience Planning (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Ahsan Arozullah
Employment - Astellas Pharma
 
Jung Wook Park
Employment - Astellas Pharma
 
Jeffrey J. Raizer
Employment - Astellas Pharma
Stock and Other Ownership Interests - Agenus; Cancer Action Now; Celldex; Exicure
 
Yung-Jue Bang
Consulting or Advisory Role - Astellas Pharma; AstraZeneca/MedImmune; BeiGene; Bristol-Myers Squibb; Daiichi Sankyo; Genentech/Roche; Green Cross; Hanmi; Merck Serono; MSD Oncology; Novartis; Samyang
Research Funding - Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Curis (Inst); Daiichi Sankyo (Inst); Genentech/Roche (Inst); Genexine (Inst); GlaxoSmithKline (Inst); Green Cross (Inst); Lilly (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)